Overview

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications.
Phase:
Phase 2
Details
Lead Sponsor:
Corcept Therapeutics